Search the Newsreel

AudioCodes Ltd (AUDC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for AudioCodes Ltd (AUDC), categorizing its income by business segments and geographical regions. As of April 6, 202X, Networking contributed 53.21% of revenue, and Technology 46.79%. Regionally, the United States accounted for 52.11% of revenue, followed by …

Bioceres Crop Solutions Corp (BIOX) Income Statement

This article provides the quarterly and annual income statements for Bioceres Crop Solutions Corp (BIOX), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes an FAQ section explaining how to interpret income statements and …

Bioceres Crop Solutions Corp (BIOX) Balance Sheet

This article provides the quarterly and annual balance sheets for Bioceres Crop Solutions Corp (BIOX), detailing assets, liabilities, and shareholders' equity. It includes financial data such as cash, receivables, inventory, and debt figures across various fiscal quarters. The content also features an FAQ section …

BIOX|Bioceres Crop Solutions Corp|Price:0.343|Chg%:-0.005

This article provides a detailed financial overview of Bioceres Crop Solutions Corp (BIOX), including its latest stock price, market cap, and key financial statements. It presents quarterly and annual data for revenue, EPS, net profit, margins, debt-to-asset ratio, and cash flow, accessible via an …

NB|NioCorp Developments Ltd|Price:5.460|Chg%:+0.100

NioCorp Developments Ltd (NB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of NioCorp Developments Ltd (NB) stock information, including its current price, market capitalization, and a section on dividends and stock splits. It states that the company has not distributed any dividends over the past five years and contains no …

BioCardia Inc (BCDA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioCardia Inc (BCDA), outlining both major individual and institutional holdings. It provides a breakdown of shareholder types, including individual investors, corporations, and hedge funds, and tracks changes in institutional shareholding over several quarters. The report also lists …

NioCorp Developments Ltd (NB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for NioCorp Developments Ltd (NB), presenting current stock performance metrics including its closing price, daily change, and market capitalization. It highlights that key valuation ratios like P/E, P/B, and P/CF have not yet been disclosed by the company. …

NioCorp stock delivers 75% return after Fair Value flagged opportunity

NioCorp Developments Ltd. (NB) stock delivered a 75.42% return between May 2024 and July 2026, after InvestingPro's Fair Value models identified it as significantly undervalued. The stock climbed from $2.36 to $4.14, driven by strategic partnerships, government funding, tax incentives, and improved fundamentals including …

NioCorp Developments Ltd (NB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for NioCorp Developments Ltd (NB), detailing analyst ratings, target prices, and historical EPS performance. Based on 5 analysts, the stock has a "Buy" consensus with a target price of USD 11.62, representing a 166.63% upside. The report also …

Bioceres Crop Solutions Corp (BIOX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Bioceres Crop Solutions Corp (BIOX) stock information, including its current market price, market capitalization, and P/E TTM. It specifically highlights the company's dividend history, noting that no dividend data is currently available and that $0.00 has been distributed …

Rice Hall James & Associates LLC Acquires 325,959 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Rice Hall James & Associates LLC significantly increased its stake in BioCryst Pharmaceuticals by 17.1% in the first quarter, adding 325,959 shares to own a total of 2,230,105 shares valued at approximately $21.2 million. Institutional ownership of BioCryst remains high at 85.88%, with numerous …

NioCorp Developments Ltd (NB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of NioCorp Developments Ltd (NB) stock, focusing on support, resistance, and various indicator readings. It presents a summary of technical indicators like MACD, RSI, and TRIX, alongside moving averages, to give a "Sell" signal for both indicators and …

BioCryst Pharmaceuticals Inc (BCRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of BioCryst Pharmaceuticals Inc (BCRX), listing its major shareholders and institutional holdings. It provides a breakdown of investor types, institutional shareholding over several quarters, and recent shareholder activities. The data highlights significant investors like BlackRock, RA Capital Management, …

NioCorp Developments Ltd. Revenue Breakdown – NASDAQ:NIOBW

This page provides financial information for NioCorp Developments Ltd. (NASDAQ: NIOBW) on TradingView. It indicates that the market is currently closed and includes sections for financials, documents, news, and community. The page offers a breakdown of revenue by source and country, noting that market …

iOCO Limited Revenue Breakdown – JSE:IOC

BioCryst Pharmaceuticals, Inc. Revenue Breakdown – MUN:BO1

BioCryst Pharmaceuticals, Inc. (MUN:BO1) reported a total revenue of €744.85 million last year, primarily driven by its Oral Small-molecule and Injectable Protein Therapeutics segment. The United States was the largest geographical contributor, accounting for €467.24 million of the revenue. This represents a significant increase …

BioCardia, Inc. Revenue Breakdown – FWB:6JU0

This article provides a financial overview and revenue breakdown for BioCardia, Inc. (FWB:6JU0) on the Frankfurt Stock Exchange. It highlights access to fundamental statistics, statements, dividends, earnings, and segment performance information for the company. The page appears to be a financial data portal, offering …

AudioCodes Ltd (AUDC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of AudioCodes Ltd (AUDC), listing major individual and institutional holders, their proportion of shares, and recent changes in their holdings. It also provides a breakdown of shareholder types, including individual investors, investment advisors, and hedge funds, alongside institutional …

AUDC|AudioCodes Ltd|Price:9.580|Chg%:+0.050

This article provides a financial overview of AudioCodes Ltd (AUDC), including its stock performance, key financial indicators, and recent earnings data. It details the company's revenue, EPS, net profit, and balance sheet items through quarterly and annual reports, highlighting changes over time. The information …

Bioceres Crop Solutions Corp. Revenue Breakdown – FWB:0G4

Bioceres Crop Solutions Corp. (FWB:0G4) generated €284.64 million in revenue last year. Its Crop Protection segment was the top performer, contributing €154.42 million, while Argentina was the largest regional contributor at €196.57 million. These figures indicate a notable decrease in overall revenue and the …

RioCan Real Estate Investment Trust Revenue Breakdown – TSX:REI.UN

BioCardia Inc (BCDA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioCardia Inc (BCDA), noting its current valuation score is 8.87, placing it 86th out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is reported at -0.99, which is significantly below its recent …

Lobbying Update: $10,000 of NIOCORP DEVELOPMENTS LTD. lobbying was just disclosed

NIOCORP DEVELOPMENTS LTD. (NB) disclosed $10,000 in lobbying expenditures for Q2 2026, focusing on funding and contracts related to NioCorp and US readiness. The article also details recent hedge fund activity in NB stock, with several large institutions increasing their positions, and analyst price …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares passed above their 200-day moving average on Thursday, trading as high as $9.48. The stock has a consensus "Moderate Buy" rating from analysts with an average target price of $20.80, despite the company reporting a wider-than-expected quarterly loss. Institutional investors …

Biocryst Pharmaceuticals Inc. (BCRX) Fundamental & Financial Data

This article provides fundamental and financial data for Biocryst Pharmaceuticals Inc. (BCRX), including its current stock price, market capitalization, dividend yield, and analyst ratings. It also highlights recent news like the appointment of a new Chief Scientific Officer and mentions that Wall Street analysts …

BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock price, analysis, news, and trading ideas for BioCryst Pharmaceuticals Inc. (BCRX). It includes current market data such as stock price, market cap, volume, 52-week high/low, PE ratio, and recent news headlines related to the company and the biotech …

BCRX Q2'26 Earnings: revenue estimate is 183.28M USD

BioCryst Pharmaceuticals, Inc. (BCRX) is scheduled to announce its Q2'26 earnings on July 30. Analysts estimate revenue to be $183.28 million and earnings per share (EPS) at $0.15 for the quarter. The article provides a table of past reported and estimated revenue and EPS …

(BCRX) Movement Within Algorithmic Entry Frameworks

The article details an algorithmic analysis of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), identifying divergent sentiment across various time horizons and an exceptional 48.0:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, …

How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals

BioCryst Pharmaceuticals recently appointed David W. Jenkins as its first Chief Scientific Officer to lead efforts in external innovation and partnerships for rare disease therapies. This move signals BioCryst's commitment to expanding its pipeline beyond its primary drug, ORLADEYO, though near-term focus remains on …

Oil-linked stocks split: HPCL, Indian Oil, Asian Paints, IndiGo decline; ONGC, OIL gain as crude jumps

Bioceres Crop Solutions (BIOX) Q1 2025 earnings summary

Bioceres Crop Solutions reported a 20% year-over-year revenue decline to $93.3 million for Q1 2025, primarily due to drought in Argentina, yet saw growth in North America and Brazil. The net loss widened to $5.3 million, and Adjusted EBITDA fell by 48%. The company …

Bioceres Crop Solutions (BIOX) Registration Filing Summary

This article provides a summary of Bioceres Crop Solutions' (BIOX) Registration Filing on December 16, 2025. It details the company's business model, product portfolio, risk factors, and market opportunities in the agricultural solutions sector. The summary also lists recent financial events and their impact …

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. …

BioCryst schedules a look at second-quarter results for Aug. 5

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. The company's prior earnings-date announcements …

Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?

BioCryst Pharmaceuticals (BCRX) has appointed David W. Jenkins as its new Chief Scientific Officer, a move generating interest among investors. The company's stock currently trades at US$9.29, with a mixed performance of 23.87% year-to-date but a 46.14% decline over five years. A common narrative …